443 related articles for article (PubMed ID: 19321326)
1. Preclinical development of T cell receptor gene therapy.
Bendle GM; Haanen JB; Schumacher TN
Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
[TBL] [Abstract][Full Text] [Related]
2. Antigen choice in adoptive T-cell therapy of cancer.
Offringa R
Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
[TBL] [Abstract][Full Text] [Related]
3. Genetic redirection of T cells for cancer therapy.
Westwood JA; Kershaw MH
J Leukoc Biol; 2010 May; 87(5):791-803. PubMed ID: 20179152
[TBL] [Abstract][Full Text] [Related]
4. Making and circumventing tolerance to cancer.
Kammertoens T; Blankenstein T
Eur J Immunol; 2009 Sep; 39(9):2345-53. PubMed ID: 19634191
[TBL] [Abstract][Full Text] [Related]
5. Generation of tumor-specific T-cell therapies.
Morris E; Hart D; Gao L; Tsallios A; Xue SA; Stauss H
Blood Rev; 2006 Mar; 20(2):61-9. PubMed ID: 15978709
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
Berry LJ; Moeller M; Darcy PK
Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
[TBL] [Abstract][Full Text] [Related]
7. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.
Peinert S; Prince HM; Guru PM; Kershaw MH; Smyth MJ; Trapani JA; Gambell P; Harrison S; Scott AM; Smyth FE; Darcy PK; Tainton K; Neeson P; Ritchie DS; Hönemann D
Gene Ther; 2010 May; 17(5):678-86. PubMed ID: 20200563
[TBL] [Abstract][Full Text] [Related]
8. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer.
Kieback E; Charo J; Sommermeyer D; Blankenstein T; Uckert W
Proc Natl Acad Sci U S A; 2008 Jan; 105(2):623-8. PubMed ID: 18182487
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T-cell therapy of cancer.
Yee C
Hematol Oncol Clin North Am; 2006 Jun; 20(3):711-33. PubMed ID: 16762731
[TBL] [Abstract][Full Text] [Related]
10. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
11. [Adoptive immunotherapy for cancer with genetically engineered T cells].
Ikeda H; Okamoto S; Mineno J; Imai N; Ito M; Yasukawa M; Takesako K; Shiku H
Rinsho Ketsueki; 2010 Nov; 51(11):1647-53. PubMed ID: 21157127
[No Abstract] [Full Text] [Related]
12. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
13. Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy.
Bai XF; Liu JQ; Joshi PS; Wang L; Yin L; Labanowska J; Heerema N; Zheng P; Liu Y
Cancer Res; 2006 Aug; 66(16):8241-9. PubMed ID: 16912204
[TBL] [Abstract][Full Text] [Related]
14. Genetically modulating T-cell function to target cancer.
Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
[TBL] [Abstract][Full Text] [Related]
15. Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy.
Engels B; Uckert W
Mol Aspects Med; 2007 Feb; 28(1):115-42. PubMed ID: 17307249
[TBL] [Abstract][Full Text] [Related]
16. Adoptive T-cell therapy for cancer: The era of engineered T cells.
Bonini C; Mondino A
Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.
Lamers CH; Sleijfer S; Willemsen RA; Debets R; Kruit WH; Gratama JW; Stoter G
J Biol Regul Homeost Agents; 2004; 18(2):134-40. PubMed ID: 15471217
[TBL] [Abstract][Full Text] [Related]
18. Enhanced T cell receptor gene therapy for cancer.
Kieback E; Uckert W
Expert Opin Biol Ther; 2010 May; 10(5):749-62. PubMed ID: 20201709
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
Chicaybam L; Sodré AL; Bonamino M
Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
[TBL] [Abstract][Full Text] [Related]
20. Supernatural T cells: genetic modification of T cells for cancer therapy.
Kershaw MH; Teng MW; Smyth MJ; Darcy PK
Nat Rev Immunol; 2005 Dec; 5(12):928-40. PubMed ID: 16322746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
